Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study to evaluate the safety and efficacy of TAK-390MR [dexlansoprazole] (60 Mg QD and 90 Mg QD) compared to placebo in maintenance of healing in subjects with healed erosive esophagitis.

Next Previous
X
Search
Trial Profile

A phase 3 study to evaluate the safety and efficacy of TAK-390MR [dexlansoprazole] (60 Mg QD and 90 Mg QD) compared to placebo in maintenance of healing in subjects with healed erosive esophagitis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexlansoprazole (Primary)
  • Indications Erosive oesophagitis
  • Focus Registrational; Therapeutic Use
  • Sponsors TAP Pharmaceutical Products

    • Most Recent Events

    • 01 Nov 2009 Primary endpoint 'Disease recurrence rate' has been met.
    • 01 Nov 2009 Results have been reported in Alimentary Pharmacology and Therapeutics.
    • 01 Sep 2009 Actual patient number (451) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top